pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 29 Non-oncology: 16
Oncology: 13
Under Consideration for Negotiation 34 Non-oncology: 23
Oncology: 11
Completed Negotiations 690 With Letter of Intent: 593
Without agreement: 97
Negotiations That Were Not Pursued 103

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Sotyktu Bristol-Myers Squibb Company Psoriasis, moderate to severe plaque
Palynziq BioMarin Pharmaceutical Inc. Phenylketonuria

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Livtencity Takeda Canada Inc. post-transplant cytomegalovirus (CMV) infection/disease
Veklury Gilead Sciences Canada Inc. COVID-19
Lynparza AstraZeneca Canada Inc. Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Paxlovid Pfizer Canada ULC Mild-to-moderate COVID-19, treatment
Oxlumo Alnylam Netherlands B.V. primary hyperoxaluria type 1
Rinvoq AbbVie Corporation Ulcerative Colitis
Rinvoq AbbVie Corporation Ankylosing spondylitis
Rinvoq AbbVie Corporation Crohn's disease
Vyalev AbbVie Corporation For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Korsuva Otsuka Canada Pharmaceutical Inc. For the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis